Pieris Pharmaceuticals (NASDAQ:PIRS) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note published on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

PIRS opened at $11.04 on Tuesday. Pieris Pharmaceuticals has a twelve month low of $10.60 and a twelve month high of $80.80. The firm has a market cap of $13.69 million, a price-to-earnings ratio of -0.49 and a beta of 0.55. The firm’s 50-day simple moving average is $13.58 and its 200-day simple moving average is $14.68.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($4.00) earnings per share for the quarter. The firm had revenue of $1.30 million for the quarter. Pieris Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 57.33%.

Hedge Funds Weigh In On Pieris Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of PIRS. Acadian Asset Management LLC raised its holdings in shares of Pieris Pharmaceuticals by 64.8% in the third quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock valued at $286,000 after buying an additional 378,339 shares during the last quarter. CM Management LLC raised its stake in shares of Pieris Pharmaceuticals by 18.1% in the third quarter. CM Management LLC now owns 649,400 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 99,400 shares during the last quarter. Finally, Summit Trail Advisors LLC acquired a new position in shares of Pieris Pharmaceuticals during the first quarter worth approximately $26,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.